NCT04298606View on ClinicalTrials.gov

A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 22, 2021

Primary Completion Date

November 22, 2029

Study Completion Date

November 22, 2029

Conditions
Chronic Obstructive Pulmonary DiseaseLung Non-Small Cell CarcinomaPneumoniaStage IB Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8Stage IIA Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8
Interventions
OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

BIOLOGICAL

Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine

Given IM

Trial Locations (1)

14263

RECRUITING

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER